Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: Vitro and vivo study

Journal of Drug Targeting

Volumn 22, Issue 9, 2014, Pages 849-858

  Wang, Fengzhen ^a,b   Chen, Li ^a,c   Zhang, Dongsheng ^a   Jiang, Sunmin ^a   Shi, Kun ^d   Huang, Yuan ^a   Li, Rui ^a   Xu, Qunwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^d XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Intraocular pressure lowing effect; Low molecular weight chitosan; Methazolamide; Ocular irritancy; Solid lipid nanoparticle

Indexed keywords

BRINZOLAMIDE; CHITOSAN; HYDROGEN PEROXIDE; METHAZOLAMIDE; SOLID LIPID NANOPARTICLE; DRUG CARRIER; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA EPITHELIUM; CORNEA PERFORATION; DEPOLYMERIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; EXPERIMENTAL RABBIT; EYE IRRITATION; GLAUCOMA; HISTOLOGY; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; NANOEMULSION; NANOENCAPSULATION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OSMOTIC PRESSURE; OXIDATION; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; STATIC ELECTRICITY; SURFACE CHARGE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; CORNEA; DOUBLE BLIND PROCEDURE; FEMALE; MALE; METABOLISM; RABBIT; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CHITOSAN; CORNEA; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG STABILITY; FEMALE; GLAUCOMA; HYDROGEN-ION CONCENTRATION; LIPIDS; MALE; METHAZOLAMIDE; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; RABBITS;

EID: 84911463961     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.939983     Document Type: Article

References (53)

1. Edelhauser HF, Maren TH. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol 1988;106:1110-15.
2. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci 1977;16:730-42.
3. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol-Chic 1977;95: 1378-82.
4. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med 1990;112:120-5.
5. Jiang S, Wang F, Zhu S, et al. Preformulation study of Methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions. Int J Pharm 2013;448:390-3.
6. Pepić I, Hafner A, Lovrić J, et al. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. J Pharm Sci 2010;99:4317-25.
7. Chen R, Qian Y, Li R, et al. Methazolamide calcium phosphate nanoparticles in an ocular delivery system. Yakugaku Zasshi 2010; 130:419-24.
8. Li R, Jiang S, Liu D, et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul 2011;28:134-41.
9. Qian Y, Wang F, Li R, et al. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev Ind Pharm 2010;36:1340-7.
10. Youshia J, Kamel AO, El SA, Mansour S. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int J Nanomedicine 2012;7:2483-96.
11. Mohd AK, Yasmin S, Asgar A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010;18: 191-204.
12. Iqbal MA, Md S, Sahni JK, et al. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012;20: 813-30.
13. Lian J, Zhang S, Wang J, et al. Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate. J Drug Target 2008;16:250-6.
14. Souto EB, Muller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010;197: 115-41.
15. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Delibery Rev 2007;59: 478-90.
16. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307-13.
17. Hao J, Fang X, Zhou Y, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 2011;6:683-92.
18. Mü ller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004;58:343-56.
19. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005a;25:133-43.
20. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185-91.
21. Pandit AA, Dash AK. Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomedicine 2011;6:1397-412.
22. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62:3-11.
23. Patil S, Babbar A, Mathur R, et al. Mucoadhesive chitosan microspheres of carvedilol for nasal administration. J Drug Target 2010;18:321-31.
24. Nagarwal RC, Kant S, Singh PN, et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009;136:2-13.
25. Ana G. Chitosan nanoparticles: a survey of preparation methods. J Drug Target 2012;20:291-300.
26. du Toit LC, Pillay V, Choonara YE, et al. Ocular drug delivery-A look towards nanobioadhesives. Expert Opin Drug Deliv 2011;8: 71-94.
27. Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013;18:290-7.
28. Mao S, Shuai X, Florian U, et al. The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharmaceut 2004;281:45-54.
29. Huang Q, Wang S, Huang J, et al. Study on the heterogeneous degradation of chitosan with hydrogen peroxide under the catalysis of phosphotungstic acid. Carbohydr Polym 2004;68:761-5.
30. Tian F, Liu Y, Hu K, Zhao B. Study of the depolymerization behavior of chitosan by hydrogen peroxide. Carbohyd Polym 2004; 57:31-7.
31. Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm 2000;199: 119-27.
32. Hämäläinen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997;38:627-34.
33. Monti D, Chetoni P, Burgalassi S, et al. Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation. Int J Pharm 2002;232:139-47.
34. O'Brien WJ, Edelhouse HF. The corneal penetration of trifluorothymidine, adenine arabinoside, and idoxuridine: a comparative study. Investig Ophthalmol Vis Sci 1977;16:1093-103.
35. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24: 371-84.
36. Zambito Y, Colo GD. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharm Biopharm 2010;75:194-9.
37. Kassem MA, Abdel Rahman AA, Ghorab MM, et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007;340:126-33.
38. Zhou W, Wang Y, Jian J, Song S. Self-aggregated nanoparticles based on amphiphilic poly (lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int J Nanomed 2013;8: 3715-28.
39. Kang B, Dai Y, Zhang H, Chen D. Synergetic degradation of chitosan with gamma radiation and hydrogen peroxide. Polym Degrad Stabil 2007;92:359-62.
40. Mahmoud AA, El-Feky GS, Kamel R, Awad GE. Chitosan/sulfobutylether-b-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011;413:229-36.
41. Tian F, Liu Y, Hu K, Zhao B. The depolymerization mechanism of chitosan by hydrogen peroxide. J Mater Sci 2003;38:4709-12.
42. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterization. Eur J Pharm Biopharm 2008;68:513-25.
43. Wu Y, Yao J, Zhou J, Dahmani FZ. Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels. Int J Nanomed 2013;8: 3587-601.
44. Hong KN, Na YP, Shin HL, Samuel PM. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol 2002;74:65-72.
45. Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186-93.
46. Sandri G, Bonferoni MC, Gökçe EH, et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 2010;27:735-46.
47. Garcia-Fuentes M, Torres D, Jos̈e Alonso M. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharmaceut 2005;296:122-32.
48. Davson H. The hydration of the cornea. Biochem J 1955;59: 24-8.
49. Zambito Y, Di Colo G. Thiolated quaternary ammonium-chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharmaceut Biopharmaceut 2010;75:194-9.
50. Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci 2011;100:3186-95.
51. Diebold Y, Jarrin M, Saez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007;28:1553-64.
52. Venkatesh S, Sizemore SP, Byrne ME. Biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics. Biomaterials 2007;28:717-24.
53. Gökçe EH, Sandri G, Egrilmez S, et al. Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res 2009;34:996-1003.